Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Stock Information for EQ Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About EQ Inc.

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
EQ Inc. Reports Profitable Fourth Quarter and 2023 Year End Financial Results
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
EQ Bank Card launches in Québec as Carte Banque EQ

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.